We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Entera Bio (ENTX) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Entera Bio Ltd. (ENTX - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Entera Bio Ltd. is one of 1017 individual stocks in the Medical sector. Collectively, these companies sit at #5 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Entera Bio Ltd. is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ENTX's full-year earnings has moved 8% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the most recent data, ENTX has returned 253.3% so far this year. Meanwhile, the Medical sector has returned an average of 10.9% on a year-to-date basis. This means that Entera Bio Ltd. is outperforming the sector as a whole this year.
Another stock in the Medical sector, argenex SE (ARGX - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 37.3%.
In argenex SE's case, the consensus EPS estimate for the current year increased 86.6% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Entera Bio Ltd. belongs to the Medical - Biomedical and Genetics industry, a group that includes 496 individual companies and currently sits at #81 in the Zacks Industry Rank. This group has gained an average of 2.3% so far this year, so ENTX is performing better in this area. argenex SE is also part of the same industry.
Going forward, investors interested in Medical stocks should continue to pay close attention to Entera Bio Ltd. and argenex SE as they could maintain their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Entera Bio (ENTX) Stock Outpacing Its Medical Peers This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Entera Bio Ltd. (ENTX - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Entera Bio Ltd. is one of 1017 individual stocks in the Medical sector. Collectively, these companies sit at #5 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Entera Bio Ltd. is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ENTX's full-year earnings has moved 8% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the most recent data, ENTX has returned 253.3% so far this year. Meanwhile, the Medical sector has returned an average of 10.9% on a year-to-date basis. This means that Entera Bio Ltd. is outperforming the sector as a whole this year.
Another stock in the Medical sector, argenex SE (ARGX - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 37.3%.
In argenex SE's case, the consensus EPS estimate for the current year increased 86.6% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Entera Bio Ltd. belongs to the Medical - Biomedical and Genetics industry, a group that includes 496 individual companies and currently sits at #81 in the Zacks Industry Rank. This group has gained an average of 2.3% so far this year, so ENTX is performing better in this area. argenex SE is also part of the same industry.
Going forward, investors interested in Medical stocks should continue to pay close attention to Entera Bio Ltd. and argenex SE as they could maintain their solid performance.